Eric B. Haura

ORCID: 0000-0003-3114-1909

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 27 papers. Top paper: “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer”.

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2742

N/A

1.8DataRank · unranked

70 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa +13 more

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors

Cell chemical biology(2021)10.1016/j.chembiol.2021.07.008

N/A

1.4DataRank · unranked

38 citations

Claire E. Knezevic, Daniel S. Bejan, Yunting Luo, Xueli Li, Silvia Novakova +10 more

Protein-altering germline mutations implicate novel genes related to lung cancer development

Nature Communications(2020)10.1038/s41467-020-15905-6

N/A

0.587DataRank · unranked

49 citations

Semanti Mukherjee, Maria Teresa Landi, Yohan Bossé, Philippe Joubert, Dakai Zhu +95 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084

N/A

0.574DataRank · unranked

45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery(2022)10.1016/j.jtcvs.2022.10.007

N/A

0.568DataRank · unranked

43 citations

Alan Nicholas, G. Alexander Patterson, Salama N. Waqar, Eric M. Toloza, Eric B. Haura +24 more

Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration

Molecular Cancer Research(2022)10.1158/1541-7786.mcr-21-0275

N/A

0.385DataRank · unranked

12 citations

Sina Hosseinian, Mia Stroud, Emma Adhikari, James J. Saller, Matthew A. Smith +14 more

MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0218

N/A

0.373DataRank · unranked

11 citations

Logan C. Tyler, Anh T. Le, Eric A. Welsh, Bin Fang, Andrew Elliott +7 more

Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2

Cell chemical biology(2023)10.1016/j.chembiol.2023.09.011

N/A

0.312DataRank · unranked

7 citations

Lily L. Remsing Rix, Xueli Li, Bin Fang, Victoria Izumi, Eric A. Welsh +6 more

Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib

ChemBioChem(2023)10.1002/cbic.202200766

N/A

0.292DataRank · unranked

6 citations

Yi Liao, J. Cao, Bin Fang, Sang Y. Yun, Fumi Kinose +6 more

TAp73 mediates anti-tumor immunity through regulation of lipid metabolism in the lung tumor microenvironment

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.11.21.689807

N/A

0.104DataRank · unranked

1 citations

Vanessa Rubio, Andrew John Davis, John H. Lockhart, Nicole R. Hackel, Rachel V. Jimenez +21 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020.v1

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

Data from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6522212

N/A

0DataRank · unranked

0 citations

Guolin Zhang, Matthew A. Smith, Alex S. López, Yun Bai, Jiannong Li +14 more

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

American Journal of Hematology(2024)10.1002/ajh.27282

N/A

0DataRank · unranked

5 citations

Lucia Mazzacurati, Tegan M. Rowsell, Nathan P. Horvat, Narmin E. Amin, Guolin Zhang +8 more

Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.04.24.590626

N/A

0DataRank · unranked

4 citations

Tatiana Miti, Sandhya Prabhakaran, Daria Miroshnychenko, M Henry, Viktoriya Marusyk +9 more

Rapid Autopsy to Define Dendritic Cell Spatial Distribution and T Cell Association in Lung Adenocarcinoma

The Journal of Immunology(2024)10.4049/jimmunol.2400234

N/A

0DataRank · unranked

0 citations

Xiaofei Song, Gina S. Nazario, Thomas Lila, Benjamin K. Chen, Tyler R. Simpson +13 more

Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancers

Research Square(2025)10.21203/rs.3.rs-6264377/v1

N/A

0DataRank · unranked

3 citations

Bina Desai, Tatiana Miti, Sandhya Prabhakaran, Daria Miroshnychenko, M Henry +12 more

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures

Nature Communications(2020)10.1038/s41467-020-16212-w

N/A

0DataRank · unranked

143 citations

Nara Yoon, Viktoriya Marusyk, Arda Durmaz, Andrew Dhawan, Daria Miroshnychenko +13 more

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology(2025)10.1002/1878-0261.70155

N/A

0DataRank · unranked

0 citations

Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo +9 more

The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling

Immunity(2020)10.1016/j.immuni.2020.03.004

N/A

0DataRank · unranked

221 citations

Rosa A. Sierra, Jimena Trillo-Tinoco, Yu Cao, Patrick Innamarato, Kyle K. Payne +19 more

Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone

Redox Biology(2020)10.1016/j.redox.2020.101440

N/A

0DataRank · unranked

46 citations

Nicolas Prieto-Farigua, Aimee Falzone, Cody Elkins, David A. Boothman, Eric B. Haura +2 more

Preventing smoking relapse in patients with cancer: A randomized controlled trial

Cancer(2020)10.1002/cncr.33162

N/A

0DataRank · unranked

21 citations

Steven K. Sutton, Lauren R. Meltzer, Úrsula Martínez, Amanda Palmer, Cathy D. Meade +5 more

Quantitative analysis of tyrosine phosphorylation from FFPE tissues reveals patient specific signaling networks

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.10.291922

N/A

0DataRank · unranked

2 citations

Danielle M. Burgenske, Ann C. Mladek, Katrina K. Bakken, Jenevieve Kuang, Judy C. Boughey +7 more

Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration

UNC Libraries(2020)10.17615/3c6y-sj88

N/A

0DataRank · unranked

0 citations

Gerold Bepler, Santo V. Nicosia, Channing J. Der, Shengyan Xiang, Hu Chen +13 more

Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.11.01.514753

N/A

0DataRank · unranked

0 citations

Maria E. Balasis, Hannah Newman, Moritz Binder, Alexis Vedder, Fumi Kinose +19 more

Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer

PLoS Computational Biology(2023)10.1371/journal.pcbi.1010690

N/A

0DataRank · unranked

18 citations

Guolin Zhang, Cüneyt Gürcan Akçora, Yu Lin, Bin Fang, John M. Koomen +3 more

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3929

N/A

0DataRank · unranked

5 citations

Maria E. Balasis, Hannah Newman, Moritz Binder, Alexis Vedder, Fumi Kinose +20 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more